Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UV1 Vaccination in Hormone-sensitive Metastatic Prostate Cancer
NCT01784913Phase 2Completed
- Sponsor
- Ultimovacs ASA
- Start
- Apr 2013
- Primary completion
- Jul 2015
- Modality
- Split/Subunit Vaccines, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of UV1 in prostate cancer (PCa), sponsored by Ultimovacs ASA. Started Apr 2013; status: completed.
02
Drugs
UV1
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01784913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01784913.